Literature DB >> 33457093

Immunotherapy with NK cells: recent developments in gene modification open up new avenues.

Lisa Marie Reindl1,2, Nawid Albinger1,2, Tobias Bexte1,2, Stephan Müller1,2, Jessica Hartmann3, Evelyn Ullrich1,2,4.   

Abstract

Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  CAR; NK cells; NK-92 cells; cell therapy

Mesh：

Substances：

Year:  2020        PMID： 33457093      PMCID： PMC7781759          DOI： 10.1080/2162402X.2020.1777651

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  112 in total

1.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors:  Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal:  Mol Ther       Date:  2019-03-20       Impact factor: 11.454

2.  Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.

Authors:  Jeremiah L Oyer; Veethika Pandey; Robert Y Igarashi; Srinivas S Somanchi; Ahmed Zakari; Melhem Solh; Dean A Lee; Deborah A Altomare; Alicja J Copik
Journal:  Cytotherapy       Date:  2016-05       Impact factor: 5.414

3.  Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism.

Authors:  Youdong Pan; Tian Tian; Chang Ook Park; Serena Y Lofftus; Shenglin Mei; Xing Liu; Chi Luo; John T O'Malley; Ahmed Gehad; Jessica E Teague; Sherrie J Divito; Robert Fuhlbrigge; Pere Puigserver; James G Krueger; Gökhan S Hotamisligil; Rachael A Clark; Thomas S Kupper
Journal:  Nature       Date:  2017-02-20       Impact factor: 49.962

4.  Restoration of lytic function in a human natural killer cell line by gene transfection.

Authors:  J H Liu; S Wei; D K Blanchard; J Y Djeu
Journal:  Cell Immunol       Date:  1994-06       Impact factor: 4.868

5.  Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells.

Authors:  Hui Liu; Bo Yang; Tingting Sun; Lin Lin; Yi Hu; Muhong Deng; Junlan Yang; Tianyi Liu; Jinyu Li; Shengjie Sun; Shunchang Jiao
Journal:  Oncol Rep       Date:  2014-10-17       Impact factor: 3.906

6.  A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Authors:  Fengtao You; Yinyan Wang; Licui Jiang; Xuejun Zhu; Dan Chen; Lei Yuan; Gangli An; Huimin Meng; Lin Yang
Journal:  Am J Cancer Res       Date:  2019-01-01       Impact factor: 6.166

7.  The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation.

Authors:  Martha Luevano; Mehri Daryouzeh; Rehab Alnabhan; Sergio Querol; Salim Khakoo; Alejandro Madrigal; Aurore Saudemont
Journal:  Hum Immunol       Date:  2011-12-28       Impact factor: 2.850

8.  Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.

Authors:  Srinivas S Somanchi; Anitha Somanchi; Laurence J N Cooper; Dean A Lee
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

9.  Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.

Authors:  Kerstin B Kaufmann; Christian Brendel; Julia D Suerth; Uta Mueller-Kuller; Linping Chen-Wichmann; Joachim Schwäble; Shweta Pahujani; Hana Kunkel; Axel Schambach; Christopher Baum; Manuel Grez
Journal:  Mol Ther       Date:  2012-12-04       Impact factor: 11.454

10.  A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.

Authors:  Emilie Decaup; Cédric Rossi; Pauline Gravelle; Camille Laurent; Julie Bordenave; Marie Tosolini; Anne Tourette; Emeline Perrial; Charles Dumontet; Mary Poupot; Christian Klein; Ariel Savina; Jean-Jacques Fournié; Christine Bezombes
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561
View more
  13 in total

1.  Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.

Authors:  Raquel S Laureano; Jenny Sprooten; Isaure Vanmeerbeerk; Daniel M Borras; Jannes Govaerts; Stefan Naulaerts; Zwi N Berneman; Benoit Beuselinck; Kalijn F Bol; Jannie Borst; An Coosemans; Angeliki Datsi; Jitka Fučíková; Lisa Kinget; Bart Neyns; Gerty Schreibelt; Evelien Smits; Rüdiger V Sorg; Radek Spisek; Kris Thielemans; Sandra Tuyaerts; Steven De Vleeschouwer; I Jolanda M de Vries; Yanling Xiao; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2022-07-04       Impact factor: 7.723

Review 2.  Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.

Authors:  Adriana Petrazzuolo; M Chiara Maiuri; Laurence Zitvogel; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2022-05-26       Impact factor: 7.723

Review 3.  Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.

Authors:  Benedikt Jacobs; Veronika Gebel; Lukas Heger; Victoria Grèze; Hansjörg Schild; Diana Dudziak; Evelyn Ullrich
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

4.  Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy.

Authors:  Vinzenz Särchen; Senthan Shanmugalingam; Sarah Kehr; Lisa Marie Reindl; Victoria Greze; Sara Wiedemann; Cathinka Boedicker; Maureen Jacob; Katrin Bankov; Nina Becker; Sibylle Wehner; Till M Theilen; Steffen Gretser; Elise Gradhand; Carsten Kummerow; Evelyn Ullrich; Meike Vogler
Journal:  Cell Death Discov       Date:  2022-01-10

Review 5.  The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses.

Authors:  Stefania Roma; Laura Carpen; Alessandro Raveane; Francesco Bertolini
Journal:  Cancers (Basel)       Date:  2021-10-09       Impact factor: 6.639

Review 6.  The Hematology of Tomorrow Is Here-Preclinical Models Are Not: Cell Therapy for Hematological Malignancies.

Authors:  Lorena Arranz
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

7.  Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.

Authors:  Nina Möker; Evelyn Ullrich; Nawid Albinger; Rita Pfeifer; Marcus Nitsche; Sarah Mertlitz; Julia Campe; Katja Stein; Hermann Kreyenberg; Ralf Schubert; Melissa Quadflieg; Dina Schneider; Michael W M Kühn; Olaf Penack; Congcong Zhang
Journal:  Blood Cancer J       Date:  2022-04-13       Impact factor: 11.037

8.  The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jun-Shuai Xue; Zi-Niu Ding; Guang-Xiao Meng; Lun-Jie Yan; Hui Liu; Hai-Chao Li; Sheng-Yu Yao; Bao-Wen Tian; Zhao-Ru Dong; Zhi-Qiang Chen; Jian-Guo Hong; Dong-Xu Wang; Tao Li
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

9.  Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.

Authors:  Maren Soldierer; Arthur Bister; Corinna Haist; Aniththa Thivakaran; Sevgi Can Cengiz; Stephanie Sendker; Nina Bartels; Antonia Thomitzek; Denise Smorra; Maryam Hejazi; Markus Uhrberg; Kathrin Scheckenbach; Cornelia Monzel; Constanze Wiek; Dirk Reinhardt; Naghmeh Niktoreh; Helmut Hanenberg
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 10.  Unleashing the power of NK cells in anticancer immunotherapy.

Authors:  Meike Vogler; Senthan Shanmugalingam; Vinzenz Särchen; Lisa Marie Reindl; Victoria Grèze; Leon Buchinger; Michael Kühn; Evelyn Ullrich
Journal:  J Mol Med (Berl)       Date:  2021-08-09       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.